esomeprazole/naproxen (Rx)

Brand and Other Names:Vimovo
  • Print

Dosing & Uses


Dosage Forms & Strengths



  • 20mg/375mg
  • 20mg/500mg

Rheumatoid Arthritis

1 tablet PO twice daily at least 30 min before meal


1 tablet PO twice daily at least 30 min before meal

Ankylosing Spondylitis

1 tablet PO twice daily at least 30 min before meal

Dosage Modification

If a dose of omeprazole needs to be < 0 mg/day consider alternate treatment

Severe renal impairment (CrCl <30 mL/min): Use not recommended

Safety and efficacy not established



Interaction Checker

and esomeprazole/naproxen

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 

            Adverse Effects


            Gastric erosion (19%); compared with 38% for equal naproxen dose without PPI

            Dyspepsia (18%); compared with 27% for equal naproxen dose without PPI

            Gastritis (17%)


            Diarrhea (6%)

            Abdominal pain (6%)

            Nausea (5%)

            Hiatal hernia (4%)

            Abdominal distension (4%)

            Flatulence (4%)

            Esophagitis (4%)

            Constipation (3%)

            Headache (3%)

            Dysgeusia (2%)

            Erosive duodenitis (2%)

            Hemorrhagic gastritis (1%)



            Duodenal ulcer

            Erosive esophagitis

            Postmarketing reports

            Gait disturbance

            Abdominal distension

            Gastroesophageal reflux




            Joint swelling

            Muscle spasms

            Renal tubular necrosis


            • Body as a Whole: Angioneurotic edema, menstrual disorders
            • Cardiovascular: Congestive heart failure, vasculitis, pulmonary edema
            • Gastrointestinal: Inflammation, bleeding (sometimes fatal, particularly in the elderly), ulceration, and obstruction of the upper or lower gastrointestinal tract, esophagitis, stomatitis, hematemesis, colitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn’s disease)
            • Hepatobiliary: Hepatitis (some cases have been fatal)
            • Hemic and Lymphatic: Eosinophilia, hemolytic anemia, aplastic anemia
            • Metabolic and Nutritional: Hyperglycemia, hypoglycemia
            • Nervous System: Depression, dream abnormalities, insomnia, malaise, myalgia, muscle weakness, aseptic meningitis, cognitive dysfunction, convulsions
            • Respiratory: Eosinophilic pneumonitis
            • Dermatologic: Alopecia, urticaria, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, fixed drug eruption, lichen planus, pustular reaction, systemic lupus erythematoses, bullous reactions, including Stevens-Johnson syndrome, photosensitive dermatitis, photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa.
            • Special Senses: Hearing impairment, corneal opacity, papillitis, retrobulbar optic neuritis, papilledema
            • Urogenital: Glomerular nephritis, hematuria, hyperkalemia, interstitial nephritis, nephrotic syndrome, renal disease, renal failure, renal papillary necrosis, raised serum creatinine
            • Reproduction (female): Infertility


            • Blood and Lymphatic: Agranulocytosis
            • Eye: Blurred vision
            • Gastrointestinal: Pancreatitis, microscopic colitis, fundic gland polyps
            • Hepatobiliary: Hepatic failure, hepatitis with or without jaundice
            • Immune System: Anaphylactic reaction/shock
            • Infections and Infestations: GI candidiasis, Clostridium difficile associated diarrhea
            • Metabolism and Nutritional Disorders: Hypomagnesemia, with or without hypocalcemia and/or hypokalemia
            • Musculoskeletal and Connective Tissue: Muscular weakness, myalgia, bone fracture
            • Nervous System: Hepatic encephalopathy
            • Psychiatric: Aggression, agitation, hallucination
            • Renal and Urinary: Interstitial nephritis
            • Reproductive System and Breast: Gynecomastia
            • Respiratory, Thoracic, and Mediastinal: Bronchospasm
            • Skin and Subcutaneous Tissue: Alopecia, erythema multiforme, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis (some fatal)
            • Nutrition: Cyanocobalamin (vitamin B-12) deficiency
            • Acute tubulointerstitial nephritis


            Black Box Warnings

            Cardiovascular Risk

            • NSAIDs may increase risk of serious cardiovascular thrombotic events, myocardial infarction (MI), and stroke, which can be fatal
            • Risk may increase with duration of use
            • Patients with risk factors for or existing cardiovascular disease may be at greater risk
            • NSAIDs are contraindicated for perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (increased risk of MI and stroke)

            Gastrointestinal Risk

            • NSAIDs increase risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal
            • GI adverse events may occur at any time during use and without warning symptoms
            • Elderly patients are at greater risk for serious GI events


            Hypersensitivity, including angioedema and anaphylactic reaction/shock has been reported with esomeprazole

            Asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs

            NSAIDs are contraindicated in late stage pregnancy (risk for closure of ductus arteriosus)

            NSAIDs are contraindicated for perioperative pain in setting of CABG surgery

            Perioperative pain in the setting of coronary artery bypass graft surgery

            Concomitant administration with rilpivirine-containing products


            NSAIDs increase risk for thrombotic events (eg, MI, stroke); consistent evidence does not exist that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events

            NSAIDs increase risk for hypertension (or worsening hypertension), CHF, and edema

            NSAIDs increase risk of GI ulceration, bleeding, and perforation

            Caution with history of inflammatory bowel disease or GI bleeding

            Long-term NSAID use may cause renal papillary necrosis or other renal injury; patients at greatest risk include elderly individuals, those with impaired renal function, hypovolemia, heart failure, liver dysfunction, or salt depletion, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers

            Caution with pre-existing asthma

            Inhibits platelet aggregation

            PPIs may increase risk of osteoporosis-related fractures

            Relief of symptoms does not eliminate the possibility of a gastric malignancy; consider additional follow-up and diagnostic testing in adult patients who have suboptimal response or early symptomatic relapse after completing treatment with a PPI

            Hypomagnesemia may occur with prolonged use (ie, >1 year); adverse effects may result and include tetany, arrhythmias, or seizures; in 25% of cases reviewed, magnesium supplementation alone did not improve low serum magnesium levels and the PPI had to be discontinued; consider monitoring magnesium levels prior to initiation of PPI treatment and periodically

            PPIs possibly associated with increased incidence of Clostridium difficile-associated diarrhea (CDAD); consider diagnosis of CDAD for patients taking PPIs with diarrhea that does not improve

            Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) reported with PPIs; avoid using for longer than medically indicated; discontinue if signs or symptoms consistent with CLE or SLE are observed and refer patient to specialist; most patients improve with discontinuation of PPI alone in 4-12 weeks; serological testing (e.g. ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations

            PPIs decreased gastric acidity increases serum chromogranin A (CgA) levels and may cause false-positive diagnostic results for neuroendocrine tumors; temporarily discontinue PPIs before assessing CgA levels

            Acute interstitial nephritis reported in patients taking PPIs; may occur at any point during PPI therapy and is generally attributed to idiopathic hypersensitivity reaction; discontinue therapy if acute interstitial nephritis develops

            Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B12) caused by hypo-or achlorhydria; rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy reported

            Patients with advanced renal disease should be adequately hydrated

            If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, discontinue treatment and monitor patient

            May elevate and/or prolong serum concentrations of methotrexate and/or its metabolite when administered concomitantly with PPIs, possibly leading to toxicity; consider a temporary withdrawal of PPI therapy with high dose methotrexate administration

            Based on the mechanism of action, the use of prostaglandin-mediated NSAIDs, including, may delay or prevent rupture of ovarian follicles that may lead to reversible infertility in some women; consider withdrawal of NSAIDs in women who have difficulties conceiving or who are undergoing investigation of infertility

            PPI therapy is associated with increased risk of fundic gland polyp; risk increases with long-term use >1 year; patient may be asymptomatic; problem usually identified incidentally on endoscopy; use shortest duration of therapy appropriate to condition being treated

            Acute tubulointerstitial nephritis (TIN) reported in patients taking PPIs; may occur at any point during PPI therapy; patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions to non-specific symptoms of decreased renal function (eg, malaise, nausea, anorexia); in reported case series, some patients were diagnosed on biopsy and in absence of extra-renal manifestations (eg, fever, rash or arthralgia); discontinue therapy and evaluate patients with suspected acute TIN


            Pregnancy & Lactation


            Use of NSAIDs during third trimester of pregnancy increases risk of premature closure of fetal ductus arteriosus; avoid use of NSAIDs in pregnant women starting at 30 weeks of gestation (third trimester); there are no adequate and well-controlled studies on this therapy in pregnant women

            There are no studies on effects of therapy during labor or delivery; in animal studies, NSAIDs, including naproxen, inhibit prostaglandin synthesis, cause delayed parturition, and increase incidence of stillbirth


            Limited data from published literature report that naproxen anion has been found in milk of lactating women at a concentration equivalent to approximately 1% of maximum naproxen concentration in plasma; esomeprazole is the S-isomer of omeprazole and limited data from published literature suggest omeprazole may be present in human milk; there is no information on effects of naproxen or omeprazole on breastfed infant or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition

            Lactation: Naproxen is distributed in breast milk, not recommended

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.



            Mechanism of Action

            Naproxen: NSAID that inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis; has antipyretic and analgesic effects

            Esomeprazole: S-isomer of omeprazole, a proton pump inhibitor; inhibits gastric acid secretion by inhibiting H+/K+-ATPase enzyme system at secretory surface of gastric parietal cells


            Half-Life: 13-15 hr

            Bioavailability: 95%

            Duration: 4-7 hr

            Onset: 1 hr

            Distribution: 0.16 L/kg

            Peak Serum Time: 1.5-3 hr; high fat meal prolongs Tmax by 10 hr

            Peak Plasma Concentration: 62-96 mcg/mL Vd: 0.16 L/kg

            Protein Bound: >99% albumin

            Metabolism: hepatic via CYP2C9, CYP1A2; also undergoes hepatic conjugation

            Clearance: 0.13 L/min/kg

            Excretion: feces < 3%, urine 95%


            Half-Life: 1.2-1.5 hr

            Bioavailability: 90%, food decreases AUC by 33-53%

            Duration: 17 hr gastric acid inhibition at steady state

            Onset: 1-2 hr

            Peak Plasma Time: 1-1.6 hr

            Vd: 16 L

            Protein Bound: 97%

            Clearance: 9-16 L/hr

            Excretion: Feces 20%, urine 80%


            • Extensively by hepatic P450 enzyme: major metabolic pathway is via CYP2C19, the rest is via CYP3A4
            • Slow metabolizers (3% of Caucasians and African-Americans) are deficient in CPY2C19 enzyme system, plasma concentration can be higher than those with the enzyme present
            • CYP2C19 inhibitor


            Oral Administration

            Tablet consists of immediate-release esomeprazole layer and enteric-coated naproxen core

            Swallow whole; do not chew, crush, dissolve, or split





            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient



            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.